ABG
APLS

Ally Bridge Group’s Apellis Pharmaceuticals APLS Stock Holding History

Ally Bridge Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-300,000
Closed -$9.89M – 32
2021
Q3 		$9.89M Hold
300,000
– – 2.91% 15
2021
Q2 		$19M Buy
+300,000
New +$15.5M 4.71% 5

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ally Bridge Group's APLS Position: Q1 2024 in Review

Ally Bridge Group sold out of Apellis Pharmaceuticals (APLS) in Q1 2024, closing a stake of 150,000 shares — an estimated $8.98M sold.

Ally Bridge Group first reported a position in APLS in Q4 2020 and held it in 5 quarters. The position peaked at $13.2M in Q4 2020. 302 funds tracked by Wall St. Rank hold APLS as of Q1 2024.

  • Ally Bridge Group reported no remaining Apellis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Ally Bridge Group sold 150,000 Apellis Pharmaceuticals shares in Q1 2024, an estimated $8.98M.
  • Ally Bridge Group first reported a position in Apellis Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Ally Bridge Group's Apellis Pharmaceuticals position peaked at $13.2M in Q4 2020.
  • 302 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2024.

Based on Ally Bridge Group's 13F filing for Q1 2024, filed 15 May 2024.